CTLA4 and prostate carcinoma: Nonetheless, long-term survival benefits and sustained complete responses have been reported in some mCRPC patients receiving a CTLA-4 inhibitor (Ipilimumab) [54], suggesting that selected prostate cancer patients may benefit from a checkpoint blockade.